Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Optimized substance forces cancer cells into death

By R&D Editors | October 2, 2012

CancerCellDeath-250

Cancer cells often have too many centrosomes. This should normally make it impossible for them to divide correctly and, as a result, lead to their death, but most of them have developed a trick to escape this fate: They form clusters of polar bodies at two poles. Image: G. Konotop, DKFZ

Many tumor cells have a defective cellular equipment. It is only by a special trick that they manage to distribute their chromosomes correctly to their daughter cells during cell division. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now developed a substance that thwarts this trick and forces cancer cells into death during cell division. The group has now reported their results in the journal Cancer Research.

When normal cells divide, the chromosomes, i.e. the genetic material, are distributed evenly to exactly two daughter cells. This process is regulated by two polar bodies, or centrosomes. When cell division begins, they are located at the opposite poles of the cell and they start forming protein fibers to each chromosome. These are then each pulled under tension to one of the poles and, thus, distributed evenly to the two newly forming daughter cells. Cancer cells often have too many centrosomes. This should normally make it impossible for them to divide correctly and, as a result, lead to their death, but most of them have developed a trick to escape this fate: They form clusters of polar bodies at two poles.

“We already discovered this clustering as a potential target for cancer treatment a couple of years ago,” says Professor Alwin Krämer, head of DKFZ’s Clinical Cooperation Unit Molecular Hematology/Oncology. Conducting further research, the scientists found out that the antibiotic griseofulvin prevents clustering.

Professor Alwin Krämer and Dr. Marc S. Raab, head of the Max Eder Junior Research Group “Experimental Therapies for Hematologic Malignancies”, collaborating with an international research team, have now been able to optimize this substance for use in cancer treatment. Project partners included scientists of Heidelberg University Hospitals. “The optimized agent GF-15 reduces the tension of the protein fibers and thus prevents clustering. As a result, cell division proceeds in a chaotic manner and this eventually leads to the death of the cancer cell,” Raab explains. His junior research group is supported by the German Cancer Aid (Deutsche Krebshilfe).

The investigators first tested the novel inhibitor in the culture dish. The substance was effective in various cell lines derived from such different types of cancer as colon cancer, cervical cancer, brain tumors, and blood cancer. In normal cells, however, GF-15 did not show any effect. The group then tested the substance in mice with colon cancer or cancer of the bone marrow. The treated animals survived significantly longer than the untreated ones and they showed no serious side effects. “GF-15 has more favorable pharmacological properties than the original griseofulvin. It is more specific and more effective,” Krämer explains. Further tests will show whether GF-15 can really be further developed into an effective anti-cancer drug.

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo

Source: German Cancer Research Center

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE